Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fujirebio completes Innogenetics acquisition

This article was originally published in The Gray Sheet

Executive Summary

Japanese diagnostics firm Fujirebio closes $112 million purchase of Belgian specialty diagnostics firm Innogenetics from Abbott Sept. 24. Abbott acquired Innogenetics in February as part of its $6.2 billion acquisition of Solvay Pharmaceuticals, but the divestiture was required to gain European Commission approval of the Solvay transaction. The Fujirebio pact was first announced in July. Both Fujirebio and Innogenetics develop diagnostics in areas such as infectious disease, genetic testing, transplantation and neuro-degeneration. Innogenetics also develops oncology tests, and has a special focus on molecular diagnostics and multiparameter testing





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts